AbbVie Inc. (NYSE:ABBV) is identified among stocks with low beta, beating market volatility. Leerink Partners increased its price target on ABBV shares from $210 to $243, citing strong business performance and Skyrizi’s market growth. The firm predicts AbbVie’s top-line growth to rise from 8% in 2025 to 11% in 2026, driven by Rinvoq and Skyrizi sales. Leerink also highlighted three oncology pipeline candidates contributing to future revenue.

Read more at Yahoo Finance: Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance